Ironwood Pharmaceuticals, Inc.
IRWD
$3.25
-$0.12-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -15.72% | -10.42% | -22.98% | -23.18% | -20.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.72% | -10.42% | -22.98% | -23.18% | -20.63% |
| Cost of Revenue | -14.62% | -21.32% | -17.40% | -4.00% | 6.33% |
| Gross Profit | -16.24% | -5.02% | -25.61% | -30.82% | -28.99% |
| SG&A Expenses | -42.99% | -38.75% | -28.02% | -11.83% | 1.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.62% | -31.03% | -23.19% | -8.37% | 3.60% |
| Operating Income | 24.07% | 50.76% | -22.47% | -49.96% | -51.15% |
| Income Before Tax | 7.40% | 30.74% | -50.17% | 102.38% | 106.88% |
| Income Tax Expenses | -28.47% | -12.95% | -35.65% | -22.29% | -22.96% |
| Earnings from Continuing Operations | 2,629.20% | 1,014.74% | -209.77% | 97.01% | 100.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,629.20% | 1,259.11% | -185.59% | 96.93% | 100.09% |
| EBIT | 24.07% | 50.76% | -22.47% | -49.96% | -51.15% |
| EBITDA | 23.44% | 49.56% | -22.17% | -49.24% | -50.52% |
| EPS Basic | 2,778.43% | 1,193.13% | -183.03% | 97.04% | 100.08% |
| Normalized Basic EPS | 30.85% | 62.17% | -36.43% | -75.67% | -72.51% |
| EPS Diluted | 1,972.88% | 629.18% | -252.13% | 96.93% | 99.91% |
| Normalized Diluted EPS | 17.49% | 48.90% | -34.95% | -74.74% | -70.27% |
| Average Basic Shares Outstanding | 1.73% | 1.96% | 2.18% | 2.34% | 2.35% |
| Average Diluted Shares Outstanding | 6.38% | 6.80% | -0.18% | -2.34% | -6.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |